ED02-03

The Nanosystems Biology Cancer Center (NSBCC) was founded three years ago by the NCI to accelerate the translation of systems biology models of cancer into clinical tool for cancer diagnosis and treatment. Over the past three years we have demonstrated that we can go, within a period of 1 to 1.5 years, from a concept on paper to Phase I trials or demonstrations in humans for three major cancer technologies: in vivo PET molecular imaging probes of cancer, siRNA-based cancer therapeutics, and highly multiplexed in vitro diagnostic assays. These advances represent major cost reductions and efficiency increases in three major aspects of cancer clinical care. However, the goal of achieving the same level of cost reductions and efficiency improvements in pushing a new therapeutic from a Phase I trial to an FDA-approved drug remains a daunting challenge. In this talk, I will discuss how the integration of in vivo and in vitro diagnostic tools with drug trials can be done to achieve this goal, and I will give examples of how we are beginning to push in this direction.

Citation Information: Cancer Prev Res 2008;1(7 Suppl):ED02-03.

Seventh AACR International Conference on Frontiers in Cancer Prevention Research-- Nov 16-19, 2008; Washington, DC

American Association for Cancer Research
2008